undamentalytics Newsletter
Sign in

Aytu Biopharma, Inc revenue

Aytu Biopharma, Inc's revenue was $57.6m in fiscal 2026, down 13.3% on the year before. Since fiscal 2014 ($58,929) it has grown at a compound 77.5% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Jun 20142015Jun 20152016Jun 20162017Jun 20172018Jun 20182019Jun 20192020Jun 20202021Jun 20212022Jun 20222023Jun 20232024Jun 20242025Jun 20252026Jun 2026
Revenue003347286697107656658
Growth on the year before—+344.2%+878.8%+25.7%+13.6%+100.0%+277.5%+137.5%+47.3%+11.1%−39.3%+1.8%−13.3%
Gross profit—0222519295267494637

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Aytu Biopharma, Inc $57.6m -13.3% -18.8%
Aquestive Therapeutics, Inc. $54.1m 22.6% 5.2%
Journey Medical Corp $68.2m 20.9% 3.5%
Rockwell Medical, Inc. $69.4m -21.1% -2.9%
Biofrontera Inc. $46.2m 17.8% 16.7%
Cumberland Pharmaceuticals Inc $39.9m -5.2% -0.6%

Compare with peers

Head to head: AQST vs AYTUAYTU vs DERMAYTU vs RMTI

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Aytu Biopharma, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aytu Biopharma, Inc.